The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so i know the higher dose which was 20 milligrams you probably still get some c2 inhibition but at the 0.5 daily you probably don't get much at the five weekly you're probably mostly just hitting one correct and not hitting two exactly like we didn't see any real hyperglycemia or hyperlipidemia which are the torque two side effects
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
is it safe to say that at the doses you give rtb 101 it has comparable m torque 1 inhibition to rad 001 at 5 milligrams weekly would that be the closest comparison
this drug rtb 101 inhibits mtor the catalytic activity of mtor it also inhibits other kinases so so it's talked about as sort of a dual kinase inhibitor but in reality it hits multiple kinases so it's a dirtier drug that's that's maybe the way to the point to make it's a dirtier drug than rapamycin which has a very specific biochemical effect on mtor and mtorc1 specifically
so so there was the the the first phase two trial was was done they hit their end point it looked like it worked and they didn't see any i mean this was a phase two trial so so the important thing was they didn't really see any substantial adverse effects as well right so then for the next trial they added in another drug called rtb 101 which is um uh one of these drugs that hits multiple kinases uh in the cell so mtor is a kinase which you know means that the biochemical activity is is to put phosphate groups on other proteins but you can think of it as a signaling sort of activity right so it mtor senses the environment and regulates the output based on the signaling function of being a kinase this drug rtb 101 inhibits mtor the catalytic activity of mtor it also inhibits other kinases so so it's talked about as sort of a dual kinase inhibitor but in reality it hits
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.